Activity Summary:
Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.

Activity Summary:
Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024 will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.

Activity Summary:
Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.

Activity Summary:
In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they’ll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Activity Summary:
In these mini-modules, expert faculty inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. By using clinical case scenarios, this activity clarifies clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Dr. Orlowski, Dr. Raje, and Dr. Voorhees lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Activity Summary:
Clinical Viewpoints MF includes a curriculum that highlights the very latest clinical data in myelofibrosis. Slides are developed and updated throughout the year by leading MF expert physicians. All content is reviewed and approved by the Clinical Viewpoints MF Planning Committee.

Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenias, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. Patients with MF also have a propensity toward leukemic transformation. Allogeneic hematopoietic stem cell transplantation (aHCT) is the only curative therapy for patients with MF; however, transplant-related morbidity and mortality precludes this option for the majority of patients. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutic targets with drug candidates in late-stage (phase II or III) clinical development for the treatment of MF. This case-based slide kit discusses the pathophysiology, burden diagnosis, current and future treatment strategies, risk stratification, adverse events associated with therapies as well as the importance of patient-centered care.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These are exciting times in the therapeutic landscape of multiple myeloma (MM) due to introduction of quadruplet regimens, novel therapies, and rapid updates to existing treatment paradigms. It is crucial that healthcare professionals are well-aware of new evidence and have the knowhow to incorporate updates into their respective practices. This activity is designed to aid busy clinicians in staying abreast of recent insights into safely integrating monoclonal antibody-based quadruplet and triplet regimens in the first-line treatment of diverse patients with newly diagnosed MM (NDMM).

This podcast will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. Healthcare providers can improve treatment decisions and patient quality of life by staying updated on these developments. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the European Hematology Association (EHA) 2024 Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
Myelofibrosis is a myeloproliferative neoplasm characterized by clonal proliferation of myeloid cells, bone marrow fibrosis and cytopenia, extramedullary hematopoiesis and hepatosplenomegaly, increased pro-inflammatory cytokine production, and systemic symptoms. In the last decade, four targeted therapies have been approved for the treatment of MF, all JAK2 inhibitors, ruxolitinib, fedratinib, pacritinib, and momelotinib. Moreover, there are a number of novel therapeutics in late-stage clinical development for the treatment of MF. This clinical clip will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA2024) Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These are exciting times in the therapeutic landscape of multiple myeloma (MM) due to introduction of quadruplet regimens, novel therapies, and rapid updates to existing treatment paradigms. It is crucial that healthcare professionals are well-aware of new evidence and have the knowhow to incorporate updates into their respective practices. This activity is designed to aid busy clinicians in staying abreast of recent insights into safely integrating monoclonal antibody-based quadruplet and triplet regimens in the first-line treatment of diverse patients with newly diagnosed MM (NDMM).

This clinical clip will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. Healthcare providers can improve treatment decisions and patient quality of life by staying updated on these developments. This clinical clip will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the European Hematology Association (EHA) 2024 Hybrid Congress, June 13-16, Madrid, Spain.

Activity Summary:
These clinical clips and podcasts are accredited, on-demand presentations that feature experts discussing recent clinical updates, hot topics and treatment options that were presented at EHA June 13-16, 2024. These activities are designed to keep healthcare professionals abreast of the most recent clinical findings.

This series of conference highlights will cover newly diagnosed multiple myeloma, pediatric idiopathic thrombocytopenia purpura (ITP), and myelofibrosis. Please click the links to participate in each of these activities. At the conclusion of the video and/or podcast, please return to that page to complete your evaluation and receive CME/CE credit.

Activity Summary:
Patients with relapsed/refractory multiple myeloma (RRMM) are associated with poor survival outcomes and are in continual need of more effective therapies. Currently, a multitude of agents including monoclonal antibodies, proteosome inhibitors, immunomodulatory agents, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and selinexor are available for patients with RRMM. More recently, the bispecific antibodies, teclistamab, elranatamab, and talquetamab have been approved for the treatment of RRMM and are also under investigation in combination with other agents and in different settings of MM.

In this podcast series, leading experts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.

Activity Summary:
Patients with relapsed/refractory multiple myeloma (RRMM) are associated with poor survival outcomes and are in continual need of more effective therapies. Currently, a multitude of agents including monoclonal antibodies, proteosome inhibitors, immunomodulatory agents, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and selinexor are available for patients with RRMM. More recently, the bispecific antibodies, teclistamab, elranatamab, and talquetamab have been approved for the treatment of RRMM and are also under investigation in combination with other agents and in different settings of MM.

In this roundtable discussion, leading experts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.

Activity Summary:
Conversations in Hematology/Oncology: Incorporating Key Updates in the Treatment of Follicular Lymphoma: A Discussion Following ASH 2023 on Assimilating Practice-Changing Breakthroughs is a podcast discussion between key opinion leaders to identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.

Activity Summary:
Myelofibrosis (MF) is a complex myeloproliferative neoplasm (MPN) that profoundly impacts the lives of patients. Recent years have witnessed advancements in risk stratification, symptom management, and treatment options for patients with MF. Unmet needs include alleviation of limiting thrombocytopenia and anemia, halting disease progression to acute leukemia, and extending survival. This has stimulated the development and investigation of a number of new agents for MF treatment. This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).

Activity Summary:
Conversations in Hematology/Oncology: Incorporating Key Updates in the Treatment of Follicular Lymphoma: A Discussion Following ASH 2023 on Assimilating Practice-Changing Breakthroughs is a discussion between key opinion leaders to identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.

Activity Summary:
Myelofibrosis (MF) is a complex myeloproliferative neoplasm (MPN) that profoundly impacts the lives of patients. Recent years have witnessed advancements in risk stratification, symptom management, and treatment options for patients with MF. Unmet needs include alleviation of limiting thrombocytopenia and anemia, halting disease progression to acute leukemia, and extending survival. This has stimulated the development and investigation of a number of new agents for MF treatment. This Conversations in MF will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).

The activity is supported by downloadable slides that have key discussion and teaching points.

Activity Summary:
Immune thrombocytopenia (ITP) is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation. Due to low levels of platelets, ITP is associated with frequent bruising and bleeding. Current evidence suggests that low platelet counts in ITP are the result of multiple factors. Heterogeneity in patient population and characteristics make it challenging for the clinicians to choose appropriate therapeutic regimen. Clinicians must make decisions on the basis of the clinical presentation of each individual patient, ideally through a shared decision-making process that considers the patient’s values and preferences with respect to the anticipated outcomes of the chosen option.

During this accredited continuing education series of four (4) podcasts, Dr. James Bussel and Dr. Cindy Neunert discuss emerging evidence for management strategies for ITP, including utilization of patient reported outcomes and shared decision making to improve outcomes.

Activity Summary:
Conversations in Acute Myeloid Leukemia: Novel Therapies Targeting the Immune System for Elderly/Unfit Patients is a podcast series between leading experts to inform and guide on breakthroughs and practice-changing updates. The expert faculty will discuss unmet needs in the treatment of elderly/unfit patients with AML and the role of novel therapies targeting the immune system in addressing them.

Activity Summary:
In this podcast series, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Conversations in Acute Myeloid Leukemia: Novel Therapies Targeting the Immune System for Elderly/Unfit Patients is a roundtable discussion between leading experts to inform and guide on breakthroughs and practice-changing updates. The expert faculty will discuss unmet needs in the treatment of elderly/unfit patients with AML and the role of novel therapies targeting the immune system in addressing them.

The activity is supported by downloadable slides that have the key discussion and teaching points.

Activity Summary:
Clinical Clips are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. This activity is designed to keep healthcare professionals on top of the most recent clinical findings.

This certified AMA/ABS/ANCC enduring video and podcast will spotlight latest advances in the treatment of ITP through a 'what you need to know' video featuring a leading expert reporting from the 2023 ASH Conference.

Activity Summary:
In this webcast archive, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Immune thrombocytopenia (ITP) is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation. Due to low levels of platelets, ITP is associated with frequent bruising and bleeding. Current evidence suggests that low platelet counts in ITP are the result of multiple factors. Heterogeneity in patient population and characteristics make it challenging for the clinicians to choose appropriate therapeutic regimen. Clinicians must make decisions on the basis of the clinical presentation of each individual patient, ideally through a shared decision-making process that considers the patient’s values and preferences with respect to the anticipated outcomes of the chosen option.

In this webcast archive, Dr. James Bussel and Dr. Cindy Neunert discuss emerging evidence for management strategies for ITP, including utilization of patient reported outcomes and shared decision making to improve outcomes.

Activity Summary:
During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.

Activity Summary:
During this webcast archive, Dr. Angela Weyand and Dr. Guy Young will discuss the latest practice-changing updates and breakthroughs in hemophilia A treatment paradigms, to ultimately improve outcomes among patients.

Please see the downloadable slides as a resource for key discussion and teaching points.

Activity Summary:
Conversations in Hematology/Oncology: Evolving Role of Bispecific Antibodies in B-cell Non-Hodgkin Lymphomas (B-NHL) is a roundtable discussion between leading experts to inform clinical practice about the rationale, safety, and efficacy of bispecific antibodies in B-NHL. The expert faculty will provide guidance on how to safely optimize therapy with bispecific antibodies to improve outcomes among patients. The activity will be supported by downloadable slides that have the key discussion/teaching points.

Activity Summary:
Clinical Viewpoints HLH/MAS includes a curriculum that highlights the very latest clinical data in hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Slides are developed and updated throughout the year by leading HLH/MAS expert physicians. All content is reviewed and approved by the Clinical Viewpoints HLH/MAS Planning Committee.

The current initial treatment for hemophagocytic lymphohistiocytosis (HLH) and/or macrophage activation syndrome (MAS) aims to suppress the excessive activation of the immune system and treat the cytokine storm. However, contemporary HLH and MAS management is an evolving science that builds off each advance in basic/clinical research and clinical experience. This case-based slide kit discusses current controversies in the management of secondary HLH, including MAS.